For H&E staining, formalin-fixed, paraffin-embedded tissue cut at 4 microns and stained using the Tissue-Tek Prisma automated slide stainer. Immunostaining was performed on the Ventana Benchmark Ultra platform (CD3) and the Leica Bond platform (CD8, PD-L1). Antibodies used include anti-human CD3 (cat. no. 103A-76, Cell Marque), anti-human CD8 (cat. no. M7103, Dako) and anti-human PD-L1 (cat. no. 13684S, Cell Signaling Technology).
Benchmark ultra
Manufactured by Leica camera
Sourced in Switzerland
The Benchmark Ultra is a high-performance laboratory equipment designed for advanced analytical applications. It provides precise and reliable measurements through its advanced technology and design. The core function of the Benchmark Ultra is to enable precise and accurate data collection for various scientific and research purposes.
Automatically generated - may contain errors
Lab products found in correlation
Bond platform, by Leica camera (2 mentions)
Anti human cd8, by Cell Marque (2 mentions)
Anti human pd l1, by Agilent Technologies (2 mentions)
Leica bond 3, by Leica camera (2 mentions)
Mum1 clone mum1p, by Agilent Technologies (1 mentions)
Bond 3, by Leica Biosystems (1 mentions)
Benchmark ultra, by Roche (1 mentions)
Bond autostainer, by Leica camera (1 mentions)
6 protocols using benchmark ultra
1
Immuno-Histochemical Tissue Analysis
2
Immunohistochemical Profiling of Lymphoma
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Hematoxylin and Eosin (H&E) stained FFPE tissue sections were reviewed to assess cyto-architectural features. Immunohistochemistry and in-situ hybridization was performed with the following panel of antibodies and probes; CD20 (clone MJ1); CD10 (clone 56C6); CD5 (clone 4C7); BCL6 (clone LN22); BCL2 (clone D5); CD21 (clone PA0171); kappa (clone ISH-5748A), lambda (clone ISH-5770A), all from Leica, IL, USA; CD79a (clone AP18); Cyclin D1 (clone SP4-R); CD138 (clone B-A38); CD21 (clone PA0171); IgG (clone 1210208A); IgG4 (clone 1123107A); Ki-67 (clone 30-9), all from Ventana, AZ, USA; and MUM-1 (clone MUM1p) from DAKO, CA, USA. Staining was performed with automated stainers (Ventana Benchmark Ultra and Leica Bond III) and visualized with the UltraView Universal and Bond polymer DAB detection kits according to the manufacturer's protocols.
3
Immuno-Histochemical Tissue Analysis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For H&E staining, formalin-fixed, paraffin-embedded tissue cut at 4 microns and stained using the Tissue-Tek Prisma automated slide stainer. Immunostaining was performed on the Ventana Benchmark Ultra platform (CD3) and the Leica Bond platform (CD8, PD-L1). Antibodies used include anti-human CD3 (cat. no. 103A-76, Cell Marque), anti-human CD8 (cat. no. M7103, Dako) and anti-human PD-L1 (cat. no. 13684S, Cell Signaling Technology).
4
PD-L1 Immunohistochemistry Protocols
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Serial sections were cut and stained using HES (hematoxylin, eosin, saffron) for histopathological diagnosis. PD-L1 staining was performed on Benchmark Ultra (Ventana Medical Systems) and Bond-III (Leica Biosystems) stainers using similar protocols outlined as follows. Benchmark Ultra (according to assay instructions): antigen retrieval 4 min at pH 9, incubation with SP142 for 8 min, and counterstaining with hematein for 8 min; Leica Bond-III: antigen retrieval 20 min at pH 9, incubation with SP142 for 15 min, and counterstaining with hematein for 10 min.
Diagnosis of BC and PD-L1 assessment was performed by a senior urogenital pathologist (EC) with training and experience in SP142 PD-L1 assessment standards [4 (link)]. Slides from the Benchmark Ultra were scored on a case-by-case basis for diagnostic purposes between 2019 and 2020. Cases were then collectively stained on the Bond-III and scored in a randomized manner, blinded to the results of the Benchmark Ultra. Although not part of the approved SP142 assay, tumor cell (TC) scores were also assessed for the purpose of this study. PD-L1 IC and TC scores were scored in categories of 0–5%, 5–10%, 10–30%, and > 30%.
Diagnosis of BC and PD-L1 assessment was performed by a senior urogenital pathologist (EC) with training and experience in SP142 PD-L1 assessment standards [4 (link)]. Slides from the Benchmark Ultra were scored on a case-by-case basis for diagnostic purposes between 2019 and 2020. Cases were then collectively stained on the Bond-III and scored in a randomized manner, blinded to the results of the Benchmark Ultra. Although not part of the approved SP142 assay, tumor cell (TC) scores were also assessed for the purpose of this study. PD-L1 IC and TC scores were scored in categories of 0–5%, 5–10%, 10–30%, and > 30%.
5
IDH1 R132H Immunohistochemistry in Tumor
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
IDH1 R132H immunohistochemistry (IHC) staining on tumor tissue sections was performed using the monoclonal mouse H09 antibody clone by Dianova (Geneva, Switzerland) at a 1:200–1:400 concentration on either a Ventana BenchMark Ultra or a Leica Bond Autostainer.
6
Immunohistochemical Biomarkers in Leukemia
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The study was approved by institutional review boards and ethics committees at all sites, and conducted in line with the Declaration of Helsinki. The study design, patients' initial characteristics, treatment procedure, response assessment and minimal residual disease (MRD) analyses are all fully described in Gressin et al. 16 Ki67 levels were assessed by immunohistochemistry (IHC) according to international recommendations. 21 Staining for p53 was performed using an automated stainer (1:8000) (Automate Ventana Benchmark Ultra) with a mouse monoclonal antibody (Leica/NovoCastra clone DO7) diluted in a CC1 Tris-EDTA buffer, pH 7.8. p53 IHC was scored by visual inspection by two observers (BB and DC). 22 Cases were scored on tissue microarrays (TMA) or whole slides depending on the type of sample. As the study was initially designed to monitor patients for up to five years, the updated long-term results presented here were obtained from routine practice records (comprising both clinical, morphological and biological follow-up). Data were obtained for the last consultation
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!